493 related articles for article (PubMed ID: 17700991)
1. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
[TBL] [Abstract][Full Text] [Related]
2. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
[TBL] [Abstract][Full Text] [Related]
3. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
[TBL] [Abstract][Full Text] [Related]
4. Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.
Beck J; Raabe A
Acta Neurochir Suppl; 2011; 110(Pt 2):147-50. PubMed ID: 21125461
[TBL] [Abstract][Full Text] [Related]
5. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
Macdonald RL; Kassell NF; Mayer S; Ruefenacht D; Schmiedek P; Weidauer S; Frey A; Roux S; Pasqualin A;
Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
[TBL] [Abstract][Full Text] [Related]
6. An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Song J; Xue YQ; Wang YJ; Xu P; Sun DK; Chen W
World Neurosurg; 2019 Mar; 123():e235-e244. PubMed ID: 30496924
[TBL] [Abstract][Full Text] [Related]
7. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
[TBL] [Abstract][Full Text] [Related]
8. Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
Higashida RT; Bruder N; Gupta R; Guzman R; Hmissi A; Marr A; Mayer SA; Roux S; Weidauer S; Aldrich EF
World Neurosurg; 2019 Aug; 128():e639-e648. PubMed ID: 31054336
[TBL] [Abstract][Full Text] [Related]
9. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
[TBL] [Abstract][Full Text] [Related]
10. Effect of clazosentan in patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials.
Wang X; Li YM; Li WQ; Huang CG; Lu YC; Hou LJ
PLoS One; 2012; 7(10):e47778. PubMed ID: 23082215
[TBL] [Abstract][Full Text] [Related]
11. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.
Chen G; Tariq A; Ai J; Sabri M; Jeon HJ; Tang EJ; Lakovic K; Wan H; Macdonald RL
Brain Res; 2011 May; 1392():132-9. PubMed ID: 21466789
[TBL] [Abstract][Full Text] [Related]
12. Method of aneurysm treatment does not affect clot clearance after aneurysmal subarachnoid hemorrhage.
Ibrahim GM; Vachhrajani S; Ilodigwe D; Kassell NF; Mayer SA; Ruefenacht D; Schmiedek P; Weidauer S; Pasqualin A; Macdonald RL
Neurosurgery; 2012 Jan; 70(1):102-9; discussion 109. PubMed ID: 21788917
[TBL] [Abstract][Full Text] [Related]
13. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
[TBL] [Abstract][Full Text] [Related]
14. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.
Sabri M; Ai J; Macdonald RL
Stroke; 2011 May; 42(5):1454-60. PubMed ID: 21454820
[TBL] [Abstract][Full Text] [Related]
15. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT
Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
[TBL] [Abstract][Full Text] [Related]
16. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats.
Schubert GA; Schilling L; Thomé C
J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733
[TBL] [Abstract][Full Text] [Related]
17. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Acta Neurochir Suppl; 2013; 115():27-31. PubMed ID: 22890639
[TBL] [Abstract][Full Text] [Related]
18. Clazosentan (Actelion).
Uhlmann D
Curr Opin Investig Drugs; 2006 Mar; 7(3):272-81. PubMed ID: 16555688
[TBL] [Abstract][Full Text] [Related]
19. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis.
Cho SS; Kim SE; Kim HC; Kim WJ; Jeon JP
World Neurosurg; 2019 Mar; 123():418-424.e3. PubMed ID: 30508597
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling.
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Nowbakht P; Roux S; Kassell N
Stroke; 2012 Jun; 43(6):1463-9. PubMed ID: 22403047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
